Breakthrough for Inficure Bio about liver and kidney fibrosis

Inficure Bio a life science company focused on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions co-presented with CymaBay Therapeutics positive data at the American Association for the study of Liver Diseases (AASLD) using the company’s proprietary NIF mouse model.

Read more

Umeå Biotech Incubator to open northern Sweden’s first life science networking pub

The northern Sweden’s first networking pub for people working in the life science industry will open its doors in Umeå on November 23rd. Behind the initiative is Umeå Biotech Incubator, which has previously been named Europe’s most innovative life science incubator.
“In Umeå we think it is important to ‘pay it forward’. We want to help and support one another and create a strong sense of unity and community. In order to succeed, we need to get to know each other”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.

Read more

Multimillion SEK investment in Vakona signals start of production

Three investors are backing Umeå-based pharmaceutical company Vakona with funding worth millions of SEK.
“We are absolutely delighted and proud to have attracted this investment. It’s a reward for many years of hard work and takes us one step closer to clinical human trials”, says Gabriella Persson, CEO of Vakona.

Read more

UmanDiagnostics launches new product that can revolutionize research in neurological diseases

Swedish-based UmanDiagnostics, a Quanterix company, has developed a new type of product that makes it easier to detect neurological diseases. Called NF-light ™ serum ELISA, it was officially launched on October 12th and will now be sold worldwide.
“Our product can be used for research inthe field of neurological diseases throughout the world. It feels very exciting, because our product is clearly revolutionary”, says Niklas Norgren, VP, Managing Director and co-founder of UmanDiagnostics.

Read more

Umeå wound healing company appoints new CEO

Umeå-based biopharmaceutical company Omnio has appointed Ulrika Norin, who has a long history of working with drug development startups, as its new CEO.

“I am excited look forward to being a part of Omnio’s team. We have made significant progress in finding identifying ways to help difficulthard-to-treat heal patients with their chronic wounds. Our work feels rewarding and important”, says Ulrika Norin.

Read more

Umeå’s booming life science industry

The life science industry in Umeå is booming. Employment has risen by more than 17 per cent per year and life science companies have attracted SEK 230 million in equity investment over the past two and a half years.
“Two years ago we set a goal that the life science industry in Umeå would generate more than SEK 1 billion and add more than 500 jobs by 2030. At today’s rate we will far exceed this goal”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator (UBI).

Read more

Xerum assigned by Swedish Public Health Agency to measure number of Swedes with antibodies against SARS-CoV-2

Umeå-based Xerum launched a home testing kit in March that detects antibodies against SARS-CoV-2 – the virus that causes Covid-19. Uptake of the kits was strong, and now the company has been given an important assignment by Sweden’s Folkhälsomyndigheten (the Swedish Public Health Agency).

“This is amazing news”, says Julia Wigren Byström, CEO of Xerum. “We will be responsible for the distribution and analysis of our self-sampling kits as part of a large study being conducted by the Swedish Public Health Agency to measure the number of people in the country who have developed antibodies”.

Read more

Lipum raises SEK 85 million and become listed on Nasdaq First North

Umeå-based biopharmaceutical company Lipum has been working towards a stock exchange listing since 2018 – and now the moment has finally arrived.

On Thursday, April 22, shares in Lipum will be traded on the Nasdaq First North Growth Market for the very first time. The company will ring Nasdaq’s opening bell, which has been specially transported to Umeå, to mark the occasion.

Read more

QureTech Bio expands workforce following major investment

Umeå-based pharmaceutical development company QureTech Bio is hiring more people as it intensifies its work to combat antibiotic resistance.
“We recently received a major investment which has created long-term security in the company. With more people in place, we can now really push on and look to the future”, says Helén Fält, who was recently appointed the new CEO of QureTech Bio.

Read more

Affärscoach på UBI – ett flexibelt och peppande jobb

Helén Fält har jobbat som affärscoach på Umeå Biotech Incubator i åtta år. I den rollen är hon ett viktigt bollplank till tidiga startups inom life science.
– Det är ett väldigt varierande, roligt och flexibelt jobb. Det är kul att få hänga med bolagen på deras tidiga resa och att göra det tillsammans med hela teamet på UBI, säger Helén Fält.

Read more

Umeå Biotech Incubator named Europe’s most innovative biotechnology incubator

Global Health and Pharma Magazine has named Umeå Biotech Incubator (UBI) as Europe’s most innovative biotechnology incubator in recognition of the positive changes it is making to the biotech industry.
“We are delighted to have been given this award, and that word of our innovative way of working has spread from Umeå to the whole of Europe. It’s really cool”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.

Read more

Umeå technology companies back young enterprise initiative to get more women into tech industry

Three high school girls from Umeå have started a UF (Young Enterprise) company that hopes to encourage more girls to study technology and qualify to work in the tech industry.
The three students have already attracted the attention of a number of large technology companies in Umeå who share their ambition.
“We are delighted that several major technology companies believe in us. It shows they are willing to make an effort to create a gender-equal technology industry”, says Aja Tomic, one of the three UF company founders.

Read more

InfiCure Bio secures US patent and publishes new data in a top scientific journal

Inficure Bio, based in Umeå in northern Sweden, has recently been granted a patent in the United States for its unique preclinical model. At the same time a study describing the basics of the model has been accepted for publication in respected online journal Scientific Reports.

“We are delighted and anticipate that thanks to this attention we will strengthen our position in the market and expect even more customers to show interest in our model”, says Sofia Mayans, CEO of Inficure Bio.

Read more